Cellectis bioresearch introduces new technology to develop cell-based assays for HTS studies Cellectis bioresearch, an expert in genome customization and a subsidiary of Cellectis , announced the publication of a scientific study describing a novel method today, predicated on meganuclease-driven targeted integration, for the generation of steady cell lines appropriate for large throughput screening generic sildenafil . The study demonstrated Cellectis bioresearch’s technology to become faster, better and reliable in deriving cell-based assays for HTS research than classical methods.
Celmatix presents six research results at ASRM’s annual meeting Celmatix, a biotechnology organization focused on helping physicians instruction patients to treatments that maximize their personal reproductive potential, announced today six analysis presentations in the annual meeting of the American Society for Reproductive Medication , being held October 12-17 in Boston. Among the data presented was a new study suggesting that up to 25 % of patients could be discontinuing assisted reproductive treatments such as for example in vitro fertilization early, while they still have a good chance of expecting. The clinical study, that was performed on a dataset of over 6,000 patients from study co-authors Reproductive Medicine Associates of NY, demonstrated that 68 % of females conceived within two cycles.